<![CDATA[CYNAERA]]>https://www.cynaera.com/blogRSS for NodeMon, 13 Apr 2026 00:39:01 GMT<![CDATA[SymCas™: Symptom Cascade Modeling for Flare Prediction in Infection-Associated Chronic Conditions]]>https://www.cynaera.com/post/symcas69dbf91e8614fb4128b18a90Sun, 12 Apr 2026 21:06:18 GMT<![CDATA[Lyme Disease Prevalence Formula (US-CCUC™ Aligned)]]>https://www.cynaera.com/post/us-ccuc-lyme69dbc6a94760d48e5e8ff289Sun, 12 Apr 2026 19:18:09 GMT<![CDATA[Personalized CRISPR Remission™ for ME/CFS: State-Dependent Gene Editing in a Flare Responsive Neuroimmune Disease]]>https://www.cynaera.com/post/crispr-remission-mecfs69d95b2975afb0779a6fd91bSat, 11 Apr 2026 14:46:34 GMT<![CDATA[CRISPR for Lupus (SLE): State-Dependent Remission, Multiomics, and Environmental Modeling in Precision Medicine]]>https://www.cynaera.com/post/crispr-remission-lupus69d7c3dfc55f668b53074bd4Thu, 09 Apr 2026 16:07:53 GMT<![CDATA[CDF-Lyme™: A Composite Diagnostic Fingerprint for Lyme Disease and Post-Treatment Lyme-Associated Illness]]>https://www.cynaera.com/post/cdf-lyme69d716aa89f9e676eca2a7b3Thu, 09 Apr 2026 04:10:05 GMT<![CDATA[Personalized CRISPR Remission™ for Sarcoidosis: A Model for State-Dependent Precision Medicine]]>https://www.cynaera.com/post/crispr-remission-sarcoidosis69d6882a89f9e676eca1592cWed, 08 Apr 2026 20:31:45 GMT<![CDATA[25+ Long COVID Phenotyping List]]>https://www.cynaera.com/post/long-covid-phenotypes69d6611e5f4a19f844e50de0Wed, 08 Apr 2026 15:09:56 GMT<![CDATA[Personalized CRISPR Remission™ in Melanoma: A State-Dependent Innovation Transforming Durable Response]]>https://www.cynaera.com/post/crispr-remission-melanoma69d507dcb75c5d3058252ff4Tue, 07 Apr 2026 16:35:16 GMT<![CDATA[The Diagnostic Multiplier™: A Framework for Adjusting Disease Prevalence Based on Real World Diagnostic Capture]]>https://www.cynaera.com/post/diagnostic-multiplier69d4f07974eeae096e50c5c6Tue, 07 Apr 2026 12:58:33 GMT<![CDATA[CRISPR Remission for Lyme : A Flare-Aware Personalized Gene Editing Innovation]]>https://www.cynaera.com/post/crispr-remission-lyme69d3b64484368b4841055af4Mon, 06 Apr 2026 17:37:48 GMT<![CDATA[CRISPR Remission for Complex Regional Pain Syndrome (CRPS) : A Flare-Aware Gene Editing Framework]]>https://www.cynaera.com/post/crispr-remission-crps69d26d81f7044e6cf7af920eSun, 05 Apr 2026 16:22:08 GMT<![CDATA[State-Dependent Oral CRISPR Delivery: A Systems Framework for Uptake, EBV Targeting, and Gene Editing Efficiency]]>https://www.cynaera.com/post/oral-crispr69d18ef8f7044e6cf7ae46b7Sun, 05 Apr 2026 04:21:12 GMT<![CDATA[Remission Pathways in Long COVID: Drug Combinations, Chronicity & Socio-Biologic Terrain]]>https://www.cynaera.com/post/remission-lc69d169fdf7044e6cf7ae0905Sat, 04 Apr 2026 19:57:25 GMT<![CDATA[CRISPR Cell Therapy for Type 1 Diabetes: Beyond Immune Evasion Using Flare -Aware & Environmental Modeling for Durable Remission]]>https://www.cynaera.com/post/crispr-type-1-diabetes69cd334955ae1fb580a47757Thu, 02 Apr 2026 21:54:05 GMT<![CDATA[Pediatric Long COVID: A Public Health Crisis Demanding Recognition]]>https://www.cynaera.com/post/pediatric-lc69ce8d6bd6854e26a0aa7960Thu, 02 Apr 2026 18:52:05 GMT<![CDATA[Long COVID as a Modelable System with CYNAERA]]>https://www.cynaera.com/post/long-covid-model69c421aba0626dd1900a503cWed, 25 Mar 2026 18:57:38 GMT<![CDATA[Enhancing CRISPR Safety in Sickle Cell Disease Using State-Dependent Intervention]]>https://www.cynaera.com/post/crispr-sickle-cell69c2ab78b1bfd68174decd5eTue, 24 Mar 2026 17:47:55 GMT<![CDATA[CDF-Peds-LC™: A Composite Diagnostic Fingerprint for Pediatric Long COVID ]]>https://www.cynaera.com/post/cdf-peds-lc69b7233702111efc4a73e221Sun, 15 Mar 2026 23:34:35 GMT<![CDATA[Global Long COVID Prevalence: The CCUC™ Tiered Framework]]>https://www.cynaera.com/post/global-longcovid69b6e20a5a996f5d6694f9bfSun, 15 Mar 2026 17:56:42 GMT<![CDATA[Microdosing Air™ : Rebuilding Environmental Tolerance in Long COVID, ME/CFS, Dysautonomia, and Mast Cell Disorders]]>https://www.cynaera.com/post/microdosing-air69b0810ba547e1dd3d7dd0a9Tue, 10 Mar 2026 23:26:17 GMT